Bridgewater Associates LP purchased a new position in MEDNAX, Inc. (NYSE:MD) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 82,537 shares of the company’s stock, valued at approximately $2,488,000. Bridgewater Associates LP owned about 0.10% of MEDNAX at the end of the most recent quarter.
Other institutional investors and hedge funds have also bought and sold shares of the company. Eagle Bay Advisors LLC acquired a new stake in shares of MEDNAX in the second quarter worth $30,000. Barrow Hanley Mewhinney & Strauss LLC increased its stake in shares of MEDNAX by 71.2% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 1,411 shares of the company’s stock worth $43,000 after purchasing an additional 587 shares during the period. Cullen Frost Bankers Inc. bought a new position in shares of MEDNAX in the second quarter worth about $50,000. Captrust Financial Advisors increased its stake in MEDNAX by 1,207.3% during the first quarter. Captrust Financial Advisors now owns 2,157 shares of the company’s stock valued at $55,000 after acquiring an additional 1,992 shares during the period. Finally, PNC Financial Services Group Inc. increased its stake in MEDNAX by 39.3% during the second quarter. PNC Financial Services Group Inc. now owns 4,664 shares of the company’s stock valued at $140,000 after acquiring an additional 1,316 shares during the period.
Shares of NYSE:MD opened at $26.49 on Thursday. MEDNAX, Inc. has a 52 week low of $12.47 and a 52 week high of $35.67. The firm’s fifty day moving average is $30.51 and its 200-day moving average is $29.72. The firm has a market cap of $2.29 billion, a PE ratio of -42.05, a price-to-earnings-growth ratio of 1.15 and a beta of 2.18. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.14 and a current ratio of 2.14.
MD has been the topic of several recent analyst reports. Truist reduced their target price on MEDNAX from $37.00 to $31.00 and set a “hold” rating on the stock in a report on Wednesday. Truist Securities lowered their price objective on shares of MEDNAX from $37.00 to $31.00 and set a “hold” rating for the company in a research report on Wednesday. SVB Leerink started coverage on shares of MEDNAX in a research note on Monday, September 27th. They issued a “market perform” rating and a $29.00 target price for the company. Stifel Nicolaus assumed coverage on shares of MEDNAX in a research note on Tuesday, June 22nd. They issued a “hold” rating for the company. Finally, Mizuho increased their price objective on shares of MEDNAX from $30.00 to $32.00 and gave the stock a “neutral” rating in a research note on Monday, August 9th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, MEDNAX has a consensus rating of “Hold” and an average price target of $29.00.
In related news, CEO Mark S. Ordan sold 95,000 shares of the company’s stock in a transaction that occurred on Monday, August 30th. The shares were sold at an average price of $35.09, for a total transaction of $3,333,550.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Roger Md Medel sold 1,270 shares of the company’s stock in a transaction on Monday, October 4th. The shares were sold at an average price of $29.00, for a total transaction of $36,830.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 105,069 shares of company stock worth $3,655,028. 2.80% of the stock is owned by corporate insiders.
MEDNAX Company Profile
MEDNAX, Inc provides physician services including newborn, anesthesia, maternal-fetal, tele radiology, pediatric cardiology and other pediatric subspecialty care. The firm’s solution include anesthesiology & pain management, prenatal, neonatal, pediatric, radiology, tele radiology, revenue cycle management and perioperative improvement consulting.
Further Reading: Yield Curve
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX, Inc. (NYSE:MD).
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.